A substantial part of people, one in five, undergoing systemic treatment for psoriasis (i.e. pills taken orally, injections or infusions) still have considerable problems with their disease, according to a recent study.
With the aid of thousands of skin biopsies and over a hundred kilograms of skin, researchers have observed how two subgroups of immune cell behave in healthy skin. This functional dichotomy is preserved in the inflammatory diseases psoriasis and vitiligo. The study opens the way for more targeted local treatments for patchy inflammatory skin disorders.
Psoriasis is a lifelong disease that is associated with significant cosmetic and physical disability and puts patients at increased risk for many major medical disorders. A multidisciplinary team of researchers has found that psoriasis patients who developed depression were at a 37 percent greater risk of subsequently developing psoriatic arthritis, compared with psoriasis patients who did not develop depression.
Scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease. The discovery could lead to new and existing medicines that target the molecule being investigated as a way of treating inflammatory diseases, such as psoriasis and inflammatory bowel disease.
The fact that men are overrepresented in psoriasis registers and consume more psoriasis care have long led researchers to believe that the common skin disease disproportionately affects men. A unique study with 5,438 Swedish psoriasis patients now reveals that women have a statistically significant lower incidence of severe psoriasis compared to men.
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered an autoimmune disease. Nevertheless, researchers were able to pinpoint a common driver of skin inflammation in both diseases.
Patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, have reported promising results when they were given a new drug.
A newly developed tissue scanner allows looking under the skin of psoriasis patients. This provides clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure.
There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.
Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient’s chances of having a long-term successful response to therapy, a pilot observational study concludes.
Different types of dendritic cells in human skin have assorted functions in the early and more advanced stages of psoriasis report researchers. The scientists suggest that new strategies to regulate the composition of dendritic cells in psoriatic skin lesions might represent an approach for the future treatment of the disease.